🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

406 results for “The George Institute” Clear

  1. 11C-SB207145, 11C-DASB

    The George Institute

    Parkinson's disease, Prodromal phase of Parkinson's disease

    phase 3 small molecule active

    1 trial

  2. 18F-AV-1451

    The George Institute

    Maladie d' Alzheimer, Alzheimer's pathology

    phase 3 small molecule active

    1 trial

  3. 18F-LBT-999

    The George Institute

    Comatose Traumatic Brain Injury patients

    phase 3 small molecule active

    1 trial

  4. 5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion

    The George Institute

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  5. 6% Hydroxy-ethyl starch (130/0.4)

    The George Institute

    Intensive Care

    phase 3 small molecule completed

    1 trial

  6. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    The George Institute

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  7. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  8. Actilyse, polvo y disolvente para solución inyectable y para perfusión, Actilyse, polvo y disolvente para solución inyectable y para perfusión

    The George Institute

    People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.

    phase 3 small molecule active

    1 trial

  9. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    The George Institute

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  10. Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  11. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  12. BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet

    The George Institute

    Chronic kidney disease

    phase 3 small molecule active

    1 trial

  13. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    The George Institute

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  14. BIOTIN, Medebiotin Fuerte solución inyectable, Medebiotín Fuerte Comprimidos

    The George Institute

    Metilcrotonilglicinuria, biotinidasa deficit

    phase 3 small molecule active

    1 trial

  15. Budesonida Aldo-Unión 0,5 mg/ml suspensión para inhalación por nebulizador, CUROSURF® 120mg/vial + 240mg/vial Endotracheopulmonary Instillation Suspension

    The George Institute

    Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.

    phase 3 small molecule active

    1 trial

  16. CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE

    The George Institute

    Severe Influenza

    phase 3 small molecule active

    1 trial

  17. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  18. COBALAMIN

    The George Institute

    Hydroxycobalamin deficiency

    phase 3 small molecule active

    1 trial

  19. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  20. CONOXIA, gas medicinal comprimido, Conoxia 100% medicinal gas, cryogenic

    The George Institute

    ILD

    phase 3 small molecule active

    1 trial

  21. COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance

    The George Institute

    Chronic liver disease

    phase 3 small molecule active

    1 trial

  22. CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE

    The George Institute

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  23. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  24. Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE

    The George Institute

    CHRONIC OMALGIA

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources